Paul Drain—an Associate Professor in the Department of Global Health, Medicine and Epidemiology at the University of Washington—and his research team have received a new grant from the CoMotion Innovation Gap Fund, a program intended to help bridge the gap between academic research grants and the level of development needed to obtain investment. Drain’s project is titled “Rapid test for measuring adherence to antiretroviral therapy and pre-exposure prophylaxis”.
In sub-Saharan Africa, many young women and adolescent girls are at high risk of HIV infection. In a new research paper published in the open access journal PLOS Medicine, Kenneth Mugwanya and co-authors report on a study aiming to investigate the feasibility of providing antiretroviral drugs via family planning clinics to prevent HIV infection in young women.
Globally, 25 percent of new HIV cases occur among young women and adolescent girls in Africa. Pre-exposure prophylaxis, or PrEP, prevents infection when taken consistently, but stigma around the disease keeps some young women from maintaining usage, according to a new review by researchers at the University of Washington.
In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months. However, PrEP use fell among participants in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored, evidence-based adherence support strategies may be needed to durably engage young African women in consistent PrEP use.
UW Department of Global Health researchers presented new HIV prevention findings at the HIV Research for Prevention (HIVR4P 2018) conference in Madrid. HIVR4P is the only global scientific conference focused exclusively on the challenging and fast-growing field of biomedical HIV prevention research. The conference supports global cross-fertilization among research on HIV vaccines, microbicides, PrEP, treatment as prevention, and other biomedical prevention approaches.
By Gerard Gallagher
Oral pre-exposure prophylaxis, or PrEP, for HIV prevention has a similar efficacy in women with “abnormal” vs. “normal” vaginal microbiota, according to recent findings.
By Tony Kirby
"The last person that I train, I want that training to be in something other than HIV", says Jared Baeten. Speaking to The Lancet Infectious Diseases from the HIV Research for Prevention Conference (HIVR4P) in Chicago, IL, where he brought a 12-strong team of his researchers, Baeten explains: “When that time comes, I want HIV to have been eliminated as public health threat, so we can focus on other diseases”.
Study involves researchers with UW International Clinical Research Center
By Bobbi Nodell
Researchers have found that breastfeeding mothers taking the antiretroviral drugs tenofovir and emtricitabine have a low risk of side effects. The study, published in PLOS, was conducted by colleagues at the UW International Clinical Research Center and partners in Kenya, Uganda and Johns Hopkins University.
By Bruce Jancin
DURBAN, SOUTH AFRICA – Oral antiretroviral pre-exposure prophylaxis (PrEP) against HIV also reduces the risk of acquiring herpes simplex virus type 2, according to research presented at the 21st International AIDS Conference.
“Given the limited interventions for primary prevention of HSV-2, efficacy against HSV-2 provides additional benefit to oral PrEP,” observed Connie Celum, MD, professor of global health and medicine at the University of Washington, Seattle.
Researchers saw 95% fewer cases than expected; model offered antiretroviral meds to HIV-infected members and preventive therapy for uninfected partners
Providing HIV medication to both members of a HIV-serodiscordant couple substantially reduced the risk of transmission within that couple, according to a study published Aug. 23 in PLOS Medicine.